Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508995 | 1.00 | GRM5 (0.47) | GRM5ALDH1A1CHRNB2CHRNA4EPAS1 | |
| SCHEMBL202404 | 0.87 | ALDH1A1 (0.61) | GRM5ALDH1A1 | |
| SCHEMBL509576 | 0.84 | ALDH1A1 (0.58) | GRM5ALDH1A1 | |
| SCHEMBL168353 | 0.82 | ALDH1A1 (0.69) | ALDH1A1NQO2 | |
| SCHEMBL16960842 | 0.79 | ALDH1A1 (0.40) | GRM5ALDH1A1CHRNB2CHRNA4EPAS1 | |
| SCHEMBL16961090 | 0.79 | ALDH1A1 (0.40) | GRM5ALDH1A1CHRNB2CHRNA4NQO2 | |
| SCHEMBL27774310 | 0.79 | CHRNB2 (0.41) | GRM5ALDH1A1CHRNB2CHRNA4EPAS1 | |
| SCHEMBL24086878 | 0.79 | EPAS1 (0.40) | EPAS1VEGFA | |
| SCHEMBL13570675 | 0.79 | DHFR (0.43) | EPAS1 | |
| SCHEMBL1584993 | 0.78 | EPAS1 (0.40) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4159738-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | Biopolar Hongye (Guangdong) Pharmaceutical Co. Ltd (CN) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | JAK3, JAK2, JAK1 | GRM5 1687/4885ALDH1A1 4145/4885CHRNB2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.